1 - 5 of 503
March 15, 2018

Bruker Appoints Gerald Herman as Interim Chief Financial Officer

March 12, 2018

Bruker and Evosep Announce New Integrated Clinical Research Proteomics Solution to Quantify Over a Thousand Proteins in Five Minutes

Minneapolis, MN – March 12, 2018 – At the 2018 US HUPO Conference, Bruker (NASDAQ: BRKR) and Evosep announce that they have executed a co-development and co-marketing agreement for the Evosep One chromatography system to work seamlessly with Bruker’s timsTOF Pro ultra-high resolution quadrupole time of flight mass spectrometer. The timsTOF Pro is powered by TIMS (Trapped Ion Mobility Separation) and the PASEF (Parallel Accumulation Serial Fragmentation) method to provide an additional dimension of fast ion mobility separation with near 100% duty cycle for faster and more sensitive complex mixture analysis. This unique combination of speed, robustness and ultra-high sensitivity is intended to deliver critical performance required for large cohort clinical proteomics studies, ushering in the era of nanoflow LC-MS/MS in clinical research.

March 8, 2018

Bruker donates S1 TITAN handheld XRF analyzer to SIGN Fracture Care International for verification of raw materials (surgical-grade stainless steel) used in medical implants

March 6, 2018

Bruker Corporation to Present at Cowen's 38th Annual Health Care Conference

BILLERICA, Mass., March 6, 2018 /PRNewswire/ -- Bruker Corporation (NASDAQ: BRKR) announced today it will participate in Cowen's 38th Annual Health Care Conference in Boston. Frank Laukien, President and CEO, will present on behalf of the company on Monday, March 12th, 2018 at 1:30 PM Eastern Time.

March 6, 2018

Newsletter Mass Spectrometry 87

In this month’s issue, we cover Bruker’s recent developments in proteomics, MALDI imaging, and biopharmaceuticals, plus recently released internal and external literature in the applied markets. We introduce the new BioPharma Compass 3.0, designed to improve biopharmaceutical analysis.